Varenicline Tartrate

Research use only, not for human use.

Varenicline Tartrate is a nicotinic AChR partial agonist, used to treat nicotine addiction.

Varenicline Tartrate is a nicotinic AChR partial agonist, used to treat nicotine addiction.

Cell Viability AssayCell Line:HUVEC Concentration:100, 200, 300, 500 μM Incubation Time:24 h Result:Did not affect cell viability at 100 and 200 μM (96.8 ± 0.1% and 93.9 ± 1.8%, respectively). Decreased cell viability to 85.7 ± 7.5% and 57.8 ± 7.7% for 300 and 500 μM, respectively.Western Blot AnalysisCell Line:HUVECConcentration:100 μM Incubation Time:1, 5, 10, 15 ,30 ,60 min, 24 h Result:Significantly activated ERK1/2 and p38 signaling with peak activity at 10–15 min and 10–30 min after treatment, respectively, lowered expression of VE-cadherin at 24 h. MLA (100 nM) significantly reversed the Varenicline-induced effects.Cell Migration Assay Cell Line:HUVEC Concentration:100 μM Incubation Time:4 h Result:Significantly increased the number of migrating cells by 2.4-fold compared with vehicle treatment. MLA (100 nM) completely blocked Varenicline-stimulated migration.

——

CP 526,555-18

Endocrinology/Hormones

AChR

mAChR

Neurological Disease

——

375815-87-5

361.35

C13H13N3·C4H6O6

>98% (HPLC)

Water: 72 mg/mL (199.25 mM); DMSO: 1 mg/mL (2.76 mM)

C1[C@@H]2CNC[C@H]1C3=CC4=NC=CN=C4C=C23.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O

(6R,10S)-7,8,9,10-tetrahydro-6H-6,10-methanoazepino[4,5-g]quinoxaline (2R,3R)-2,3-dihydroxysuccinate

(-20℃)

With Ice Pack

≥ 2 years